Vicept Therapeutics has reported positive results from a Phase II clinical trial evaluating V-101 cream, a topical cream for the treatment of facial redness known as Type I Rosacea (ETR).
The results showed a statistically significant improvement in the primary endpoint, which was defined as a reduction in facial erythema over an eight-hour period in patients with ETR, compared to placebo
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
In addition, V-101 demonstrated a safety profile similar to the placebo cream, without any evidence of “rebound” or tachyphylaxis.
The prospectively randomised, multi-centred, double-blinded and placebo-controlled trial was designed to assess the dose-response relationship of four concentrations of V-101 cream versus.
A total of 183 patients with moderate to severe erythema were enrolled at seven investigational centres across the US.
Patients were divided among five groups and self-administered one of four concentrations of V-101 cream or placebo cream once daily for 28 days.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
